To determine the impact of the Bcr/Abl status on the efficacy of PHA-739358, we treated human ALL cells including BLQ1, Pt2 (Bcr/Abl+, T315I mutation), UCSF02, TXL2 (Bcr/Abl+, wild type), US7, US7R (non-Bcr/Abl) and mouse 8093 and Bin2 cells (Bcr/Abl+, wild type) with increasing concentrations of PHA-739358 for 72 hours. This evidence concerns the gene NME9 and acute lymphoblastic leukemia.